October 06, 2017 BY Valentina Kirilova

Biostage moves from NASDAQ to OTCQB Marketplace

Biostage, Inc., a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, announced today that the Company received written notification from The Nasdaq Stock Market LLC (NASDAQ) indicating that the NASDAQ Hearings Panel (the "Panel") has determined to delist the Company's common stock from The…

Read more